Protecting Innovation for Psychedelic Therapies Fast-Tracked Under New Executive Order

On April 18, 2026, President Trump signed an Executive Order to accelerate FDA approval of certain psychedelic therapies for mental illness. Keep reading to find out what the Order entails, and how an accelerated approval process for psychedelics might impact your intellectual property (IP) strategy.... By: Sterne, Kessler, Goldstein & Fox P.L.L.C.